Chronic inflammatory demyelinating polyneuropathy
Chronic inflammatory demyelinating polyneuropathy
Also known as:CIDP, chronic inflammatory demyelinating polyradiculoneuropathy, China Second Rare Disease Catalog item 13
Chronic inflammatory demyelinating polyneuropathy is an immune-mediated peripheral nerve disorder that often causes weakness, numbness, imbalance, and reduced reflexes that progress or relapse over more than 8 weeks.
Start Here
A quick guide to the next step: which department to start with, what to prepare, and what to ask.
Progressive limb weakness, numbness, or unsteady walking for more than 8 weeks should be assessed by neurology, preferably a neuromuscular or neuroimmunology specialist.
CIDP mainly affects the myelin coating of peripheral nerves. When immune inflammation damages myelin, nerve signals slow or block, causing weakness, numbness, poor balance, falls, or clumsier hand function.
CIDP is treatable. Common first-line treatments include IVIG, corticosteroids, and plasma exchange, with rehabilitation and long-term reassessment for many patients.
CIDP is usually not inherited. The workup often includes ruling out inherited neuropathies, diabetic neuropathy, vitamin deficiency, infections, blood disorders, POEMS, and other mimics.
Because symptoms may progress slowly, CIDP can be mistaken for spine disease, common neuropathy, diabetic neuropathy, or incomplete recovery from Guillain-Barre syndrome. The timeline and nerve conduction studies are key.
This page helps patients and families organize care leads. It does not replace a clinician’s diagnosis or treatment plan. For testing, medication, referrals, emergency care, and support applications, follow qualified clinicians, medical institutions, support organizations, and official sources.
Diagnosis Path
Organized around the practical patient journey: identify clues, avoid common delays, then prepare for care.
When to Suspect It
- Weakness, numbness, tingling, or imbalance in both legs or arms worsens for more than 8 weeks.
- Stairs, rising from a chair, lifting arms, writing, buttoning, using utensils, or walking distance becomes harder.
- Reflexes are reduced or absent, with muscle wasting, fatigue, nerve pain, or a relapsing-remitting course.
- A neuropathy diagnosis has been made but the cause is unclear, or spine disease does not explain the full pattern.
Common Wrong Turns
- Only doing spine imaging without nerve conduction studies and EMG.
- Attributing all numbness to diabetes or aging while missing proximal weakness and absent reflexes.
- Treating symptoms lasting beyond 8 weeks as a single acute Guillain-Barre-like episode.
- Stopping treatment without follow-up after improvement, leading to delayed care when relapse occurs.
Departments to Start With
- Neurology
- Neuroimmunology
- Neuromuscular clinic
- Rehabilitation medicine
Before the Visit
- Create a timeline of weakness, numbness, progression, relapses, falls, and walking distance.
- Bring EMG and nerve conduction results, CSF results, spine MRI, glucose, thyroid, vitamin, immune, infection, and blood disorder screening.
- Record prior infections, vaccines, cancer or blood disorder clues, medication history, and family history of neuropathy.
- Track response and side effects after IVIG, steroids, plasma exchange, or other treatments.
Tests to Ask About
- Nerve conduction studies and EMG looking for demyelination, conduction block, or slowed conduction velocity.
- CSF testing, often used to assess protein level and exclude other inflammatory or infectious causes.
- Blood and urine tests to rule out diabetes, vitamin deficiency, thyroid disease, infections, monoclonal proteins, and blood cancers.
- Nerve root or plexus MRI/ultrasound, selected antibody testing, and rarely nerve biopsy.
Questions for the Doctor
- Do I have typical CIDP or a variant, and which mimics still need to be excluded?
- Do my nerve conduction studies support demyelination, and when should they be repeated?
- Which treatment fits me best: IVIG, steroids, plasma exchange, or another option?
- How will response be measured, and what is the plan for tapering or maintenance?
- What rehabilitation, fall prevention, pain, and fatigue strategies should I use?
Basic Information
Medical Notes
More complete medical explanations are kept here for discussion with clinicians.
Symptoms
CIDP commonly causes weakness and abnormal sensation that progress for more than 8 weeks. Typical patients may have both proximal and distal weakness, making stairs, rising from a chair, lifting the arms, gripping objects, or walking difficult. Numbness, tingling, poor balance, nerve pain, muscle wasting, fatigue, and reduced reflexes are also common.
The course may be progressive or relapsing. Some variants are mainly sensory, mainly motor, or asymmetric, so neuromuscular specialist assessment is important.
Diagnosis
Diagnosis depends on the time course, neurological examination, and electrodiagnostic evidence. Nerve conduction studies and EMG look for demyelination, such as slowed conduction, conduction block, or prolonged distal latencies. Symptoms progressing over more than 8 weeks help distinguish CIDP from acute neuropathies.
Elevated CSF protein, nerve root imaging changes, treatment response, and exclusion of mimics can support the diagnosis. Clinicians also assess for diabetes, vitamin deficiency, thyroid disease, infections, inherited neuropathies, monoclonal gammopathy, blood cancers, and POEMS.
Treatment
First-line CIDP treatments commonly include intravenous or subcutaneous immunoglobulin, corticosteroids, and plasma exchange. The choice depends on speed and severity, comorbidities, treatment risks, access, and patient preferences. Response should be measured with strength, walking, sensory, and sometimes repeat electrodiagnostic outcomes.
Some patients need maintenance therapy or additional immune-modulating medicines. Physical therapy, strength and balance training, orthotics, pain care, and fall prevention are also important for function.
Long-term Care
Long-term care focuses on confirming true treatment response, avoiding over- or undertreatment, monitoring side effects, and recognizing relapse. Patients can track walking distance, stair ability, hand function, falls, pain, and fatigue.
Sudden worsening, loss of treatment response, or new systemic symptoms should prompt reassessment of the diagnosis and coexisting conditions.
Fertility and Family
CIDP is usually not inherited, and relatives generally do not need genetic screening. However, a family history of high arches, lifelong neuropathy, early weakness, or similar symptoms should be shared so inherited neuropathies can be considered.
Pregnancy planning or long-term immune therapy should be discussed with neurology and obstetrics to review medication safety and relapse planning.
When to Seek Urgent Care
Seek emergency care for rapid worsening to inability to walk, swallowing difficulty, breathing trouble, marked chest symptoms, altered consciousness, severe infection signs, possible blood clot symptoms, or a severe reaction after plasma exchange or immune therapy.
Prognosis
Many people respond to immune treatment, but relapse or maintenance treatment may be needed. Early diagnosis, response monitoring, and rehabilitation improve function.